Guidelines for hypertension management in patients with chronic kidney disease in China (2023).
10.3760/cma.j.cn441217-20220630-00650
- Collective Name:Chinese Society of Nephrology
- Publication Type:Journal Article
- MeSH:
Humans;
Antihypertensive Agents/therapeutic use*;
Hypertension/therapy*;
Renal Insufficiency, Chronic/therapy*;
Blood Pressure;
Risk Factors;
China/epidemiology*
- From:
Chinese Journal of Hepatology
2023;39(1):48-80
- CountryChina
- Language:Chinese
-
Abstract:
The population of chronic kidney disease (CKD) with hypertension in China is characterized by complex etiology, high incidence rate, low awareness and control rate. How to diagnose and treat hypertension in CKD patients properly and improve their prognosis is particularly urgent. Several clinical guidelines or expert consensus on the diagnosis, treatment and management of hypertension have been issued. Some of them involve the diagnosis and treatment of hypertension in CKD patients, but they still can not meet the demand for diagnosis and treatment of hypertension in CKD patients. Based on the situation of hypertension in CKD patients in China, the Chinese Society of Nephrology organized an expert group to formulate this guideline. This guideline systematically introduces the diagnostic criteria, epidemiology, risk factors, poor prognosis of hypertension, the purpose, timing and control goals of antihypertensive therapy in CKD patients, as well as blood pressure control goals for special populations, non drug treatment and drug treatment of hypertension. This guideline aims to further strengthen the management of hypertension in CKD patients, standardize the diagnosis and treatment standards, formulate reasonable treatment plans, effectively control hypertension, reduce complications, so as to delay the progress of kidney diseases and improve the long-term prognosis of hypertension in Chinese CKD patients.
